EUVIMEDEUVIMED entdecken
Fallbericht

Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report

Adeline Blandinières, Sophie Combe, Noémie Chanson, Olivier Lambotte, Cécile Lavenu-Bombled

Hämostaseologie · 01.04.2026 · 46 (02) · 111-114

DOI: 10.1055/a-2266-7984 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Hämostaseologie, erschienen am 01.04.2026. Verfasst von Adeline Blandinières und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Public Assistance Hospitals of Paris (AP-HP), Bicêtre Hospital, Le Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: von Willebrand Diseases, von Willebrand Factor, Waldenstrom Macroglobulinemia. Die Arbeit nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic management of acquired von Willebrand syndrome (AVWS) can be challenging, particularly in cases of AVWS associated with monoclonal IgM such as Waldenström macroglobulinemia (WM) where several therapeutic options may be ineffective. Here, we describe the case of an 88-year-old patient who developed AVWS during follow-up for WM. The presence of a severe bleeding symptomatology not controlled by several therapies (plasma-derived von Willebrand factor, plasmapheresis) led us to introduce a supplementation with recombinant von Willebrand factor, vonicog α (Veyvondi, Takeda, Japan), starting at a dose of 50 IU/kg/d. This supplementation allowed clinical (no further bleeding) and biological (hemoglobin level, von Willebrand factor parameters) improvements. Because of the persistence of bleeding risk factors, the treatment was maintained at a prophylactic dose (20 UI/kg three times a week), without recurrence of bleeding events for a period of 9 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand Diseasesvon Willebrand FactorWaldenstrom MacroglobulinemiaHumansAged, 80 and overTreatment OutcomeMaleRecombinant Proteins

Substanzen

von Willebrand FactorRecombinant Proteins

Autor:innen und Institutionen

  • Department of Hematology, Public Assistance Hospitals of Paris (AP-HP), Bicêtre Hospital, Le Kremlin-Bicêtre, France.
  • University of Paris-Saclay, INSERM Hemostasis, Inflammation and Thrombosis Unit (HITh) U1176, Le Kremlin-Bicêtre, France.
  • Department of Internal Medicine and Clinical Immunology, Public Assistance Hospitals of Paris (AP-HP), Bicêtre Hospital, Le Kremlin-Bicêtre, France.
  • University of Paris-Saclay, INSERM, CEA, UMR 1184, Le Kremlin-Bicêtre, France.

Zitieren

APA

Blandinières, A., Combe, S., Chanson, N., Lambotte, O., & Lavenu-Bombled, C. (2026). Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report. Hämostaseologie, 46(02), 111-114. https://doi.org/10.1055/a-2266-7984

Vancouver

Blandinières A, Combe S, Chanson N, Lambotte O, Lavenu-Bombled C. Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report. Hämostaseologie. 2026;46(02):111-114. doi:10.1055/a-2266-7984

BibTeX
@article{Blandinires2026,
  author = {Blandinières, Adeline and Combe, Sophie and Chanson, Noémie and Lambotte, Olivier and Lavenu-Bombled, Cécile},
  title = {Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report},
  journal = {Hämostaseologie},
  year = {2026},
  volume = {46},
  number = {02},
  pages = {111--114},
  doi = {10.1055/a-2266-7984}
}
Kostenlos starten →